Logo image of ANIP

ANI PHARMACEUTICALS INC (ANIP) Stock Fundamental Analysis

NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD

65.19  +0.23 (+0.35%)

After market: 65.19 0 (0%)

Fundamental Rating

5

ANIP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ANIP get a neutral evaluation. Nothing too spectacular is happening here. ANIP is evaluated to be cheap and growing strongly. This does not happen too often!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ANIP had positive earnings in the past year.
ANIP had a positive operating cash flow in the past year.
In the past 5 years ANIP reported 4 times negative net income.
Of the past 5 years ANIP 4 years had a positive operating cash flow.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

The Return On Assets of ANIP (-0.50%) is better than 80.31% of its industry peers.
ANIP has a Return On Equity of -1.45%. This is amongst the best in the industry. ANIP outperforms 81.87% of its industry peers.
ANIP's Return On Invested Capital of 2.10% is fine compared to the rest of the industry. ANIP outperforms 78.76% of its industry peers.
Industry RankSector Rank
ROA -0.5%
ROE -1.45%
ROIC 2.1%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

ANIP has a Operating Margin of 3.58%. This is in the better half of the industry: ANIP outperforms 79.79% of its industry peers.
ANIP's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 60.17%, ANIP is in the better half of the industry, outperforming 68.39% of the companies in the same industry.
In the last couple of years the Gross Margin of ANIP has declined.
Industry RankSector Rank
OM 3.58%
PM (TTM) N/A
GM 60.17%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

ANIP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ANIP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ANIP has more shares outstanding
The debt/assets ratio for ANIP is higher compared to a year ago.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 1.91 indicates that ANIP is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ANIP (1.91) is better than 65.80% of its industry peers.
ANIP has a debt to FCF ratio of 9.35. This is a negative value and a sign of low solvency as ANIP would need 9.35 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.35, ANIP belongs to the top of the industry, outperforming 80.83% of the companies in the same industry.
A Debt/Equity ratio of 1.38 is on the high side and indicates that ANIP has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.38, ANIP is doing worse than 75.13% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 9.35
Altman-Z 1.91
ROIC/WACC0.22
WACC9.57%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.66 indicates that ANIP has no problem at all paying its short term obligations.
The Current ratio of ANIP (2.66) is comparable to the rest of the industry.
A Quick Ratio of 1.98 indicates that ANIP should not have too much problems paying its short term obligations.
ANIP has a Quick ratio (1.98) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 1.98
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.54%, which is quite good.
Measured over the past 5 years, ANIP shows a small growth in Earnings Per Share. The EPS has been growing by 0.59% on average per year.
ANIP shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.85%.
Measured over the past years, ANIP shows a very strong growth in Revenue. The Revenue has been growing by 24.37% on average per year.
EPS 1Y (TTM)19.54%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%40.5%
Revenue 1Y (TTM)56.85%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%43.43%

3.2 Future

The Earnings Per Share is expected to grow by 12.58% on average over the next years. This is quite good.
The Revenue is expected to grow by 10.09% on average over the next years. This is quite good.
EPS Next Y27.95%
EPS Next 2Y17.81%
EPS Next 3Y17.22%
EPS Next 5Y12.58%
Revenue Next Year31.52%
Revenue Next 2Y18.85%
Revenue Next 3Y14.69%
Revenue Next 5Y10.09%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

ANIP is valuated reasonably with a Price/Earnings ratio of 11.46.
89.64% of the companies in the same industry are more expensive than ANIP, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.41. ANIP is valued rather cheaply when compared to this.
ANIP is valuated reasonably with a Price/Forward Earnings ratio of 9.03.
ANIP's Price/Forward Earnings ratio is rather cheap when compared to the industry. ANIP is cheaper than 84.46% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.19. ANIP is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.46
Fwd PE 9.03
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ANIP is valued cheaply inside the industry as 80.83% of the companies are valued more expensively.
82.90% of the companies in the same industry are more expensive than ANIP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 21.19
EV/EBITDA 17.8
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

ANIP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ANIP's earnings are expected to grow with 17.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.41
PEG (5Y)19.51
EPS Next 2Y17.81%
EPS Next 3Y17.22%

More info and screens

0

5. Dividend

5.1 Amount

ANIP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (7/14/2025, 4:16:51 PM)

After market: 65.19 0 (0%)

65.19

+0.23 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners95.9%
Inst Owner Change0%
Ins Owners7.84%
Ins Owner Change8.23%
Market Cap1.41B
Analysts84.29
Price Target83.93 (28.75%)
Short Float %11.15%
Short Ratio5.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-25.25%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.96%
Min EPS beat(2)11.36%
Max EPS beat(2)20.55%
EPS beat(4)4
Avg EPS beat(4)14.54%
Min EPS beat(4)5.26%
Max EPS beat(4)20.97%
EPS beat(8)8
Avg EPS beat(8)28.1%
EPS beat(12)11
Avg EPS beat(12)36.05%
EPS beat(16)12
Avg EPS beat(16)13.46%
Revenue beat(2)2
Avg Revenue beat(2)6.75%
Min Revenue beat(2)6.54%
Max Revenue beat(2)6.96%
Revenue beat(4)4
Avg Revenue beat(4)4.78%
Min Revenue beat(4)0.74%
Max Revenue beat(4)6.96%
Revenue beat(8)8
Avg Revenue beat(8)7.86%
Revenue beat(12)12
Avg Revenue beat(12)8.42%
Revenue beat(16)14
Avg Revenue beat(16)6.64%
PT rev (1m)0%
PT rev (3m)1.59%
EPS NQ rev (1m)-1.52%
EPS NQ rev (3m)-9.33%
EPS NY rev (1m)1.03%
EPS NY rev (3m)3.23%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-0.35%
Revenue NY rev (1m)0.52%
Revenue NY rev (3m)2.52%
Valuation
Industry RankSector Rank
PE 11.46
Fwd PE 9.03
P/S 1.74
P/FCF 21.19
P/OCF 17.48
P/B 3.18
P/tB N/A
EV/EBITDA 17.8
EPS(TTM)5.69
EY8.73%
EPS(NY)7.22
Fwd EY11.07%
FCF(TTM)3.08
FCFY4.72%
OCF(TTM)3.73
OCFY5.72%
SpS37.48
BVpS20.48
TBVpS-7.19
PEG (NY)0.41
PEG (5Y)19.51
Profitability
Industry RankSector Rank
ROA -0.5%
ROE -1.45%
ROCE 2.66%
ROIC 2.1%
ROICexc 2.45%
ROICexgc 6.82%
OM 3.58%
PM (TTM) N/A
GM 60.17%
FCFM 8.21%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 1.38
Debt/FCF 9.35
Debt/EBITDA 5.83
Cap/Depr 18.61%
Cap/Sales 1.74%
Interest Coverage 1.15
Cash Conversion 76.92%
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 1.98
Altman-Z 1.91
F-Score4
WACC9.57%
ROIC/WACC0.22
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.54%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%40.5%
EPS Next Y27.95%
EPS Next 2Y17.81%
EPS Next 3Y17.22%
EPS Next 5Y12.58%
Revenue 1Y (TTM)56.85%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%43.43%
Revenue Next Year31.52%
Revenue Next 2Y18.85%
Revenue Next 3Y14.69%
Revenue Next 5Y10.09%
EBIT growth 1Y-44.16%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year33.94%
EBIT Next 3Y19.79%
EBIT Next 5Y14.11%
FCF growth 1Y55608.3%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y781.43%
OCF growth 3Y168.16%
OCF growth 5Y7.01%